Technology · Health & biomedicine / Therapeutics & platforms

TIL therapy (tumor-infiltrating lymphocytes)

TIL therapy — autologous tumor-infiltrating T-cells with polyclonal specificity; the first approved drug Lifileucel (Amtagvi, Iovance, FDA 2024) is a breakthrough in metastatic melanoma.

Maturity 5/9 Risk: medium Advanced therapies US · CN · EU Science: why it works → verified 2026-06-19 · 0 Sources (0 independent)

1 · What it gives

TIL therapy (Tumor-Infiltrating Lymphocytes) isolates, expands and re-infuses autologous T-cells that have deeply infiltrated a tumor. Unlike CAR-T (one surface antigen), TILs recognise a broad spectrum of a tumor’s personal neoantigens (polyclonal specificity) — minimising immune escape. The first approved drug in the class is Lifileucel (Amtagvi, Iovance), FDA-approved in early 2024 for metastatic melanoma after checkpoint inhibitors. A course costs about $515,000; the expansion phase (REP) is compressed from 22 to14 days in optimised protocols.

Key platforms of TIL therapy:

Standard TIL (Standard TIL): a polyclonal pool from dissociated tumor.
CRISPR-TIL (Genome-edited TIL): PD-1 or Cbl-b knockout for resistance to immunosuppression.
Repertoire expansion (REP): rapid expansion with IL-2 + anti-CD3 (REP phase).
Closed systems (Closed Systems): CliniMACS Prodigy for automated GMP manufacture.

Sectoral value chain#

[tumor resection] ──> [dissociation + TIL isolation] ──> [REP phase (IL-2 + anti-CD3)]
                                                              │
                                                  (cryopreservation / QC)
                                                              │
                                                              ▼
[patient after lymphodepletion] <─── [TIL infusion] <─── [autologous product release]

Value chain levels#

Level	Description	Key inputs/outputs
Tumor Resection	surgical removal of the patient’s tumor tissue	In: patient. Out: tumor tissue.
TIL Isolation	dissociation, TIL pool isolation (+/− CRISPR PD-1 KO)	In: tissue. Out: TIL pool.
REP Expansion	IL-2 + anti-CD3 expansion (14–22 days)	In: TIL pool. Out:10^9–10^{11}$ cells.
QC & Cryostorage	sterility, viability, phenotype; freezing	In: expanded TIL. Out: cryobanked product.
Conditioning & Infusion	patient lymphodepletion, TIL infusion + IL-2	In: product, patient. Out: infused patient.
Follow-up	response and toxicity monitoring (CRS, ICANS)	In: patient. Out: therapy outcome.

Cross-cutting technologies of the sector:

CRISPR-TIL: PD-1/Cbl-b knockout to overcome the immunosuppressive microenvironment.
Closed systems: CliniMACS Prodigy — automated sterile manufacture.
Decentralised manufacture: Hospital Exemption (EU) — in-hospital production.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

1
Tumor resection
Surgical removal of the tumor tissue from the autologous TIL donor patient.
2
TIL isolation
Tumor dissociation, TIL pool isolation; optionally CRISPR PD-1/Cbl-b knockout.
3
REP expansionFermentation & cultivation
Expansion with IL-2 and anti-CD3 over 14–22 days to10^9–10^{11}$ cells.
Who can do this step matched automatically
Advanced Enzyme Technologies (NSE) India
✓ ISO 9001 500 m3
“Technology: microbial fermentation with ~500 m3 fermentation capacity; 15+ patents; developed/upscaled probiotic production technologies.”
Loopworm India
6,000 tonnes/year industrial scale
“At Loopworm, we are building the future of sustainable biomanufacturing.”
CHITOSE Japan
industrial scale
“AI x BIOMANUFACTURING”
Ajinomoto Japan
industrial scale
“It specializes in amino acid fermentation technology, applying it to seasonings, processed foods, frozen foods, and healthcare solutions.”
Jiangsu Trautec China
industrial scale
“2025-07-16 [喜讯｜创健医疗入选国家工信部第一批“AI+生物制造”典型案例企业动态新闻中心江苏创健医疗科技股份有限公司 — Jiangsu Trautec (创健医疗) is highlighted for being selected by China's Ministry of Industry and Information …”
TurtleTree Singapore
industrial scale
“At TurtleTree, we are pioneering the future of health with our breakthrough product, LF+: the world’s first vegan lactoferrin created through cutting-edge precision fermentation …”
4
QC & cryopreservationTesting & analytics
Sterility, viability, phenotype; product frozen until infusion.
Who can do this step matched automatically
Turion Labs Singapore
“Turion Labs is a Singapore-headquartered biotech innovation platform that provides shared laboratory infrastructure, contract research organization (CRO) services, and regulatory …”
5
Lymphodepletion
The patient undergoes lymphodepletion (chemotherapy) to make a “niche” for the TILs.
6
Infusion
Intravenous infusion of autologous TILs with IL-2 support; CRS/response monitoring.

4 · Who delivers

Matched suppliers (matched automatically)

PBS Biotech	United States	Services / consulting	active
Sartorius	Germany	Producer	active

Leading companies and institutes (from the brief)

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
Iovance	🇺🇸 USA	Lifileucel (Amtagvi)	first approved TIL; iCTC plant	Commercial
Instil Bio	🇺🇸 USA	TIL platforms	optimised expansion	Scaling
MD Anderson	🇺🇸 USA	academic TIL	survival datasets	Research
Memorial Sloan Kettering	🇺🇸 USA	CRISPR-TIL	PD-1/Cbl-b knockout	Research
NKI	🇳🇱 Netherlands	academic TIL	Hospital Exemption	Research
CCIT	🇩🇰 Denmark	academic TIL	decentralized production	Research

5 · Rules & route to market

United States

The US leads: first global TIL approval (Lifileucel/Amtagvi, FDA 2024) and industrial infrastructure.

Iovance Amtagvi, iCTC mega-plant, Medicare coverage#

Iovance: Lifileucel (Amtagvi) — the first approved TIL drug; iCTC mega-plant (Philadelphia) for thousands of patients.
MD Anderson / MSK: the largest long-term-survival clinical datasets.
Medicare/Medicaid: TIL covered under dedicated DRG codes at a course cost of ~$515,000.

European Union

The EU classifies TIL as ATMP; strict EMA oversight + academic programs.

EMA ATMP oversight, NKI/CCIT academic programs, Hospital Exemption#

EMA ATMP: REP-phase sterility in closed systems (CliniMACS Prodigy).
NKI (Netherlands) / CCIT (Denmark): academic TIL programs at cancer institutes.
Hospital Exemption: decentralized hospital production lowers cost.

China

China is rapidly building clinical TIL experience in solid tumors.

National TIL protocols, fast REP, MOST funding#

Compressed REP: domestic protocols cut REP from 22 to14 days.
Solid tumors: clinical activity in lung and cervical cancer.
China MOST: subsidies for national TIL protocols.

6 · Money: tenders & grants

Grant	Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the … National Institutes of Health · United States	Aug 18, 2027 306 days
Grant	First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based … National Institutes of Health · United States	Oct 15, 2027 364 days

7 · Tech stack & innovations

The stack rests on REP expansion, CRISPR modification and closed GMP systems.

REP expansion (Rapid Expansion):
- IL-2 + anti-CD3 over 14–22 days to10^9–10^{11}$ cells.
CRISPR-TIL:
- PD-1 or Cbl-b knockout for resistance to tumor immunosuppression.
Closed systems:
- CliniMACS Prodigy — automated sterile manufacture under EMA ATMP.